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Time from first presentation in primary
care to treatment of symptomatic colorectal
cancer: effect on disease stage and survival
P Murchie*,1, E A Raja1, D H Brewster2, N C Campbell1, L D Ritchie1, R Robertson3, L Samuel4, N Gray1
and A J Lee1
1Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen AB25 2ZD, UK;
2Scottish Cancer Registry, Information Services Division of NHS National Services Scotland, Gyle Square, 1 South Gyle Crescent,
Edinburgh EH12 9EB, UK; 3Scottish Collaboration for Public Health Research and Policy (SCPHRP), 20 West Richmond Street,
Edinburgh EH8 9DX, UK and 4Department of Oncology, Aberdeen Royal Infirmary, Aberdeen, AB25 2ZN, UK
Background: British 5-year survival from colorectal cancer (CRC) is below the European average, but the reasons are unclear. This
study explored if longer provider delays (time from presentation to treatment) were associated with more advanced stage disease
at diagnosis and poorer survival.
Methods: Data on 958 people with CRC were linked with the Scottish Cancer Registry, the Scottish Death Registry and the acute
hospital discharge (SMR01) dataset. Time from first presentation in primary care to first treatment, disease stage at diagnosis and
survival time from date of first presentation in primary care were determined. Logistic regression and Cox survival analyses, both
with a restricted cubic spline, were used to model stage and survival, respectively, following sequential adjustment of patient and
tumour factors.
Results: On univariate analysis, those with o4 weeks from first presentation in primary care to treatment had more advanced
disease at diagnosis and the poorest prognosis. Treatment delays between 4 and 34 weeks were associated with earlier stage
(with the lowest odds ratio occurring at 20 weeks) and better survival (with the lowest hazard ratio occurring at 16 weeks). Provider
delays beyond 34 weeks were associated with more advanced disease at diagnosis, but not increased mortality. Following
adjustment for patient, tumour factors, emergency admissions and symptoms and signs, no significant relationship between
provider delay and stage at diagnosis or survival from CRC was found.
Conclusions: Although allowing for a nonlinear relationship and important confounders, moderately long provider delays did not
impact adversely on cancer outcomes. Delays are undesirable because they cause anxiety; this may be fuelled by government
targets and health campaigns stressing the importance of very prompt cancer diagnosis. Our findings should reassure patients.
They suggest that a health service’s primary emphasis should be on quality and outcomes rather than on time to treatment.
There is an important, but modest, reduction in colorectal cancer
(CRC) mortality after screening suggesting that for asymptomatic
CRC at least early diagnosis is beneficial (Hewitson et al, 2007;
Atkin et al, 2010; Tørring et al, 2011, 2012). Whether diagnostic
and treatment delays really matter after CRC symptoms and signs
have developed is much less certain. Despite this, the NHS is
driven by the belief that short diagnostic and treatment delays are
critical, with strict targets for referral, investigation and manage-
ment of suspected CRC (Department of Health, 2007; The Scottish
Government, 2008; Richards, 2009). Two recent meta-analyses
found no association between delays and stage at diagnosis or
survival in CRC (Ramos et al, 2007, 2008). Since then, several
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others have failed to demonstrate that delays influence stage at
diagnosis and survival in CRC (Wattercheril et al, 2008; Iversen
et al, 2009; Simunovic et al, 2009; Terhaar sive Droste et al, 2010).
The methodological rigour of existing studies is sub-optimal,
however, paying scant attention to important patient and tumour
characteristics and treating the effect of time to treatment on
disease stage and survival as linear. More recent work from
Denmark concludes that it is not (Tørring et al, 2011, 2012). These
studies, which are strengthened by clearer definitions of the delays
experienced by patients in the diagnosis and treatment of cancer,
found a non-monotonic relationship between provider delay and
3-year mortality from colorectal cancer (Weller et al, 2012; Tørring
et al, 2011, 2012). In the Danish study, survival was poorest among
those treated most rapidly, improving briefly as time to diagnosis
increased, before deteriorating again after a few weeks. This
suggested that delays before diagnosis are important if an initial
poor prognostic group with aggressive disease is excluded. The
authors, however, had limited scope to adjust for factors associated
with aggressive disease, such as tumour grade or symptoms and
signs at presentation.
The present study explored whether patients with longer times
between first presentation in primary care and treatment (provider
delay) had more advanced stage at diagnosis and poorer survival
for CRC when important confounders such as tumour grade and
symptoms and signs were taken into account.
MATERIALS AND METHODS
Data were linked from four datasets. The CRUX (Comparing Rural
and Urban Cancer Care) dataset, collected in 2000 and 2001,
provides primary care data on people diagnosed in Northern
Scotland with CRC between 1997 and 1998 (Robertson et al, 2004).
Data includes details of consultations with relevant symptoms and
signs before diagnosis (Scottish Intercollegiate Guideline Network
(SIGN), 2003; Robertson et al, 2004). Date of first presentation in
primary care was the first record of a relevant sign or symptom of
CRC preceding diagnosis. Subsequently dates of first hospital
referral, diagnosis, and first treatment were recorded. Patients with
symptoms and signs for 42 years before treatment were excluded.
This dataset was linked to the Scottish Cancer Registry to obtain
modified Dukes’ stage and tumour grade (Brewster et al, 2002;
Brewster and Stockton, 2008). Further linkage was made to the
General Register Office for Scotland Death Registry (for date of
death, primary and secondary causes), and SMR01, an episode-
based record of all discharges from Scottish hospitals (Kendrick
and Clarke, 1993; Kendrick, 1997). The Scottish Cancer Registry
and CRUX datasets were linked directly using the Scottish Cancer
Registry ID number. The SMR01 and death records were linked
using computerised probability linkage (Harley and Jones, 1996).
Linkage was performed at ISD Scotland, the final dataset supplied
as an SPSS (IBM SPSS Statistics for Windows, Version 20.0, IBM
Corp, Armonk, NY, USA) datafile with all personal identifying
information removed.
Statistical analysis. The two main outcomes were stage at
diagnosis (Dukes A, B, C or D) and all cause survival from date
of first presentation in primary care. Survival was measured from
date of presentation rather than date of diagnosis or treatment to
overcome lead-time bias. A sensitivity analysis was also conducted
measuring survival from date of diagnosis or treatment and is
presented as Supplementary Note 1.
The main predictor variable was defined as time from first
presentation in primary care to first treatment or to definitive
diagnosis as recorded in the Scottish Cancer Registry if no
treatment was given. A range of potential confounders were
available including tumour site, stage at diagnosis, grade of
differentiation, place of presentation, specific symptoms and signs
at presentation, type of admission (emergency or elective), age,
gender, smoking status, Carstairs deprivation quintile and
Charlson co-morbidity index (Charlson et al, 1987; Morris and
Carstairs, 1991).
Data were analysed using Stata (Version 11; StataCorp, College
Station, TX, USA). Provider delay (time from first presentation in
primary care to treatment) was converted into weeks and treated as
a continuous variable. Stage was collapsed into a binary variable
(early (A or B) vs advanced (C or D)). A stringent P-valuep0.01
was used to denote statistical significance throughout the analysis.
This was chosen to minimise the chance of a Type 1 error arising
from multiple testing. To explore the relationship between provider
delay and stage at diagnosis, logistic regression was used. An
unadjusted odds ratio (OR) and 99% confidence interval (CI) for
provider delay (weeks) was calculated and three sequentially
adjusted models were run. Potential confounders were those that
were deemed to be clinically important and/or showed a univariate
relationship with outcome at a conservative Pp0.10. In model 2,
age, smoking status, Carstairs deprivation quintile, Charlson
co-morbidity index and place of presentation were included.
Model 3 added tumour grade and type of hospital admission,
while model 4 further added a range of symptoms and signs
(constipation, rectal bleeding, abdominal pain, anorexia, weight
loss and abdominal mass).
Cox survival analysis was used to examine the relationship
between provider delay and mortality with hazard ratios (HRs) and
99% CIs being calculated. As before, four sequential models were
fitted adjusting for patient factors, tumour grade and type of
hospital admission, symptoms and signs. The proportional hazard
assumption is based on Schoenfeld residuals (no violations were
detected in the current analyses) (Hess, 1995).
To model the nonlinear relationship between provider delay and
either stage or mortality, a restricted cubic spline (RCS) procedure
was adopted (Dupout, 2008). This uses multiple polynomial line
segments within the range of provider delay, the boundaries of
these line segments being called knots. Knots are placed at equally
spaced centiles of the distribution of provider delay. In the current
analyses, five knots were considered and placed at the 0th, 25th,
50th, 75th and 100th percentile points of provider delay. A spline
function was assumed to be significant if the P-value for the model
w2 was p0.01 and the association is assumed to be nonlinear if the
spline coefficients differ significantly from each other based on the
Wald test for linearity. A provider delay value of 4 weeks was used
as the reference value to estimate odds of late stage disease in the
logistic RCS analyses and the HR of mortality in the RCS Cox
analyses. A further stratified analysis of the relationship between
provider delay, stage and mortality was conducted treating colonic
and rectal tumours separately (Supplementary Note 2).
RESULTS
A total of 958 patients with symptomatic CRC were included in the
survival analysis. Of 958 patients, 868 had data on stage (Table 1).
The median (IQR) provider delay was 17 (8–39) weeks. Over half
the cohort was male (56.6%), the mean (s.d.) age was 69.9 (10.8)
years and over 75% of patients were in the three least deprived
quintiles.
Stage as the outcome. In univariate logistic regression analysis,
younger age, co-morbidities and higher grade tumours were
significant predictors of advanced stage (Table 1).
Table 2 presents the results of the logistic RCS analyses to
explore the association of provider delay on advanced stage at
diagnosis. In the fully adjusted model 4, provider delay of 40 and
60 weeks was associated with later stage disease at presentation, but
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the ORs did not reach statistical significance. In addition, older age
was associated with earlier stage disease, whereas higher grade
tumours and a higher Charlson co-morbidity index were
independently associated with more advanced stage. The nonlinear
relationship between provider delay and stage are illustrated by the
spline curves shown in Figures 1 and 2. These curves plot the
length of the provider delay on the X-axis against the odds of
patients having later stage disease on the Y-axis. Figure 1 shows the
spline curves for each of the four sequential models from the
unadjusted model (solid line) through varying degrees of
adjustment to the fully adjusted model (long dash dotted line).
Overall, provider delay was significantly associated with stage in
the unadjusted model (P¼ 0.002) and the P-value for the nonlinear
association was P¼ 0.04. Treatment delays between 4 and 34 weeks
(with the lowest OR occurring at 20 weeks) were associated with
earlier stage. Treatment delays beyond this were associated with
more advanced disease at diagnosis, although the odds began to
diminish again after about 1 year. Adjusting for confounders
reduced the odds of advanced disease for those with short delays,
but had little other impact. Figure 2 shows the fully adjusted model
of provider delay on odds (99% CI) of late stage disease after
adjustment for patient and tumour factors, emergency admissions
and symptoms and signs. The CIs were wide such that there did
not appear to be a strong relationship between provider delay and
stage of CRC at diagnosis after multi-adjustment. The analysis of
the relationship between provider delay and stage for colonic and
Table 1. Univariate analysis showing the relationship between stage at diagnosis and various factors for patients with CRC
Factor Overall (n¼868) Stage A or B (n¼443) Stage C or D (n¼425) OR (99% CI)
Provider delay median (IQR) weeks 17 (8, 39) 17 (9, 39) 17 (8, 39) 0.99 (0.99, 1.00)
Age median (IQR) years 71 (64, 78) 73 (66, 79) 70 (62, 76) 0.98 (0.96, 0.99)
Gender
Male 491 (56.6) 235 (53.1) 256 (60.2) 1.34 (0.94, 1.91)
Female 377 (43.4) 208 (47.0) 169 (39.8) 1.00
Smoking status
Non-smoker 326 (37.6) 177 (40.0) 149 (35.1) 1.00
Current smoker 137 (15.8) 65 (14.7) 72 (16.9) 1.32 (0.78, 2.23)
Ex-smoker 191 (22.0) 99 (22.4) 92 (21.7) 1.10 (0.69, 1.77)
Not known 214 (24.7) 102 (23.0) 112 (26.4) 1.30 (0.83, 2.05)
Carstairs quintile
1 (least deprived) 207 (24.3) 98 (22.6) 109 (26.0) 1.00
2 230 (27.0) 133 (30.7) 97 (23.1) 0.66 (0.40, 1.08)
3 206 (24.2) 100 (23.0) 106 (25.3) 0.95 (0.57, 1.58)
4 149 (17.5) 69 (15.9) 80 (19.1) 1.04 (0.60, 1.82)
5 (most deprived) 61 (7.2) 34 (7.8) 27 (6.4) 0.71 (0.34, 1.52)
Charlson index (median (IQR) 1 (0, 2) 1 (0, 2) 1 (0, 2) 1.14 (1.05, 1.24)
Place of presentation
GP surgery 676 (77.9) 350 (79.0) 326 (76.7) 1.00
GP home visit 111 (12.8) 59 (13.3) 52 (12.2) 0.95 (0.56, 1.61)
GP out of hours visit 33 (3.8) 12 (2.7) 21 (4.9) 1.88 (0.72, 4.87)
Other 22 (2.5) 10 (2.3) 12 (2.8) 1.29 (0.42, 3.95)
Not known 26 (3.0) 12 (2.7) 14(3.3) 1.25 (0.45, 3.52)
Tumour grade
I 42 (4.9) 36 (8.2) 6 (1.44) 1.00
II 550 (64.2) 293 (66.7) 257 (61.5) 5.26 (1.65, 16.74)
III/IV 147 (17.2) 53 (12.1) 94 (22.5) 10.6 (3.14, 36.01)
Ungradeable 118 (13.8) 57 (13.0) 61 (14.6) 6.42 (1.88, 21.99)
Type of hospital admission
Elective admission 631 (72.7) 328 (74.0) 303 (71.3) 1.00
Emergency admission 237 (27.3) 115 (26.0) 122 (28.7) 1.15 (0.78, 1.70)
Symptom
Constipation 118 (13.6) 49 (11.1) 69 (16.2) 1.56 (0.93, 2.61)
Rectal bleeding 252 (29.0) 140 (31.6) 112 (26.4) 0.77 (0.53, 1.14)
Abdominal pain 251 (28.9) 118 (26.6) 133 (31.3) 1.25 (0.85, 1.85)
Anorexia 34 (3.9) 12 (2.7) 22 (5.2) 1.96 (0.76, 5.03)
Weight loss 79 (9.1) 37 (8.4) 42 (9.9) 1.20 (0.65, 2.21)
Abdominal mass 49 (5.7) 29 (6.6) 20 (4.7) 0.71 (0.32, 1.52)
Abbreviations: CI¼ confidence interval; GP¼general practitioner; IQR¼ inter-quartile range; OR¼odds ratio. Values are n (%) unless otherwise stated.
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rectal tumours separately lacked statistical power, but provided no
real evidence of any difference between the two cancer sites
(Supplementary Note 2).
Mortality as the outcome. In univariate survival analysis, older
age, a higher Charlson co-morbidity index, higher grade tumours,
presentation through a general practitioner home visit, emergency
admission and the symptom anorexia were each associated with a
significantly increased hazard of mortality (Table 3).
Table 4 presents the results of the sequential Cox survival
analyses. In the fully adjusted model, age, male gender, a higher
Charlson co-morbidity index, higher tumour grade and the
symptoms and signs of anorexia and abdominal mass were each
independently associated with an increased hazard of mortality. In
the unadjusted model, provider delay was inversely associated with
mortality (Po0.001) and the association was nonlinear (Po0.001).
Figure 3 displays separate spline curves for each of the four survival
models, illustrating the effect of sequential adjustment for potential
Table 2. Logistic regression model with a 4 knot restricted cubic spline for the association of provider delay on stage (4 week delay as reference)
Model 1 Model 2 Model 3 Model 4
OR (99% CI) OR (99% CI) OR (99% CI) OR (99% CI)
Provider delay (weeks)
4 1.00 1.00 1.00 1.00
20 0.73 (0.50 1.07) 0.86 (0.57 1.31) 0.84 (0.54 1.32) 0.87 (0.54 1.39)
40 1.29 (0.88 1.88) 1.54 (1.03 2.32) 1.46 (0.95 2.25) 1.46 (0.93 2.31)
60 1.41 (0.92 2.17) 1.72 (1.09 2.72) 1.61 (0.99 2.60) 1.58 (0.96 2.61)
Age 0.97 (0.95 0.99) 0.97 (0.95 0.99) 0.97 (0.95 0.99)
Gender
Male 1.32 (0.89 1.95) 1.30 (0.87 1.95) 1.28 (0.85 1.92)
Female 1.00 1.00 1.00
Smoking status
Non-smoker 1.00 1.00 1.00
Current smoker 1.13 (0.64 1.98) 1.25 (0.69 2.25) 1.19 (0.66 2.17)
Ex-smoker 1.04 (0.62 1.72) 1.05 (0.62 1.78) 1.06 (0.62 1.81)
Not known 1.43 (0.88 2.33) 1.57 (0.95 2.60) 1.52 (0.91 2.53)
Carstairs deprivation quintile
1 (least) 1.00 1.00 1.00
2 0.72 (0.42 1.21) 0.78 (0.45 1.33) 0.77 (0.44 1.33)
3 1.08 (0.63 1.85) 1.18 (0.68 2.06) 1.21 (0.69 2.13)
4 1.16 (0.65 2.08) 1.23 (0.67 2.25) 1.22 (0.66 2.26)
5 (most) 0.66 (0.30 1.48) 0.67 (0.30 1.53) 0.65 (0.29 1.50)
Place of presentation
GP surgery 1.00 1.00 1.00
GP home visit 1.07 (0.59 1.94) 1.09 (0.58 2.03) 1.08 (0.58 2.04)
GP out of hours visit 1.85 (0.67 5.08) 2.03 (0.70 5.88) 2.03 (0.69 5.91)
Others 1.21 (0.35 4.11) 1.06 (0.29 3.81) 1.17 (0.32 4.28)
Missing 1.18 (0.40 3.48) 1.11 (0.35 3.52) 1.24 (0.38 4.02)
Charlson Index 1.17 (1.07 1.27) 1.18 (1.08 1.30) 1.18 (1.07 1.30)
Grade
Grade I 1.00 1.00
Grade II 6.16 (1.87 20.25) 6.16 (1.85 20.46)
Grade III/IV 14.29 (4.05 50.42) 14.46 (4.07 51.43)
Ungradeable 6.78 (1.90 24.12) 7.05 (1.96 25.32)
Emergency admission 0.88 (0.53 1.47) 0.82 (0.49 1.38)
Constipation 1.54 (0.86 2.73)
Rectal bleeding 0.84 (0.52 1.35)
Abdominal Pain 1.16 (0.73 1.84)
Anorexia 1.76 (0.61 5.06)
Weight loss 1.33 (0.65 2.73)
Abdominal Mass 0.83 (0.34 2.03)
Abbreviations: CI¼ confidence interval; GP¼general practitioner; OR¼odds ratio. Values shown are odds ratio (99% confidence interval). Model 1: unadjusted model for time to treatment
with 4 knots. Model 2: model 1 adding place of presentation, patient age, patient gender, smoking status, deprivation and Charlson index. Model 3: model 2 adding tumour grade and type of
hospital admission. Model 4: model3 adding constipation, rectal bleeding, abdominal pain, anorexia, weight loss and abdominal mass.
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confounders. In the unadjusted model, treatment delays o4 weeks
were associated with poor survival, but this association was no
longer present after adjusting for confounders. An initial U-shaped
survival curve in the unadjusted model (with lowest HR at B16
weeks) became less pronounced with sequential adjustment.
Figure 4 shows the spline curve for the fully adjusted model along
with the 99% CIs. For people with CRC, after simultaneous
adjustment for patient factors, tumour factors and symptoms,
longer provider delay was not significantly associated with survival
from CRC. Due to smaller numbers, the analysis of the relationship
between provider delay and mortality for colonic and rectal
tumours separately lacked statistical power, but provided no real
evidence of any difference between the two cancer sites
(Supplementary Note 2).
DISCUSSION
Summary of main findings. We have confirmed that there is a
nonlinear relationship between time before treatment and both
disease stage and survival. Colorectal cancer patients with very
short provider delays have a poor prognosis explained by their
personal characteristics and features of the tumour, including
grade and symptoms. These patients apart, however, we have not
found that longer provider delays are associated with poorer
survival. In both analyses, CIs were wide so the possibility of long
provider delays having deleterious effects on stage at diagnosis and
survival cannot be excluded. However, any true effect from
provider delay on CRC outcome seems likely to be small in
population terms, certainly when compared with patient delays
which are likely to have a much greater role (Simon et al, 2010).
When explored separately, there appeared to be no obvious
difference in the relationship between provider delay, mortality
and stage between colonic or rectal tumours.
Strengths and limitations. Some limitations of the current
analyses should be acknowledged. An historical sample (patients
diagnosed with symptomatic CRC between 1997 and 1998) was
used predating important changes in management, and it is
important to emphasise that the patterns of delays experienced by
patients may be different now. For example, bowel screening will
increase the proportion of people diagnosed pre-symptomatically,
although fewer than 15% of CRC cases in Scotland since 2007 were
screen detected (Information and Statistics Division (ISD), 2013).
Treatment has also improved since 1998, particularly more
widespread adjuvant chemotherapy, and pre-operative radio-
therapy in rectal cancer. Both advances, however, may even
further attenuate any relationship between provider delay and
outcome. It does not seem likely that there will have been
important changes in the biology of CRC in that time, but the
possibility should not be discounted out-of-hand. Most impor-
tantly, while our results provide reassurance, they should not
engender complacency. The quality of clinical data continues to
improve along with scope to link those data from primary care,
secondary care and national registries. The methods reported here
should be replicated using increasingly detailed and sophisticated
linked clinical datasets so that knowledge on the relationship
between delay and outcome continues to accumulate. This was an
observational retrospective study dependent on good quality data
within primary care-held medical records. For those presenting a
long time before treatment, their initial symptoms and signs may
have been due to other causes, which may account for falling odds
of late stage disease and improving survival observed with provider
delays of more than a year.
There are, however, several strengths to the analysis. This was a
population-based sample, including all patients diagnosed within
the study period and not limited to those treated within tertiary
cancer centres. The sample was large with high levels of complete
follow-up and was effectively linked to high quality routine
datasets. The extent of the data enabled a detailed analysis
adjusting for a greater array of potential explanatory variables than
previously. Our choice of variables included in the regression
model was pragmatic. Tumour stage as a predictor variable was
excluded from the multivariate survival models since, if time
between presentation and treatment is an important factor for
survival, then its effect would be via more advanced disease stage.
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Figure 1. Spline curve of logistic regression of provider delay (weeks)
on odds of having later stage (CþD) disease at diagnosis. Model 1
(solid line): unadjusted model with four knots (provider delay of 4 weeks
used as reference). Model 2 (dashed line): adjusted for place of
presentation, patient age, patient gender, smoking status, Carstairs
deprivation quintile and Charlson index. Model 3 (dotted line): further
adjusted for tumour grade and type of admission. Model 4 (long dash
and dotted line): further adjusted for symptoms and signs of
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Figure 2. Spline curve of logistic regression of provider delay (weeks)
on odds ratio (shaded area are 99% CIs) of having later stage (CþD)
disease at diagnosis after multi-adjustment for potential confounders.
Reference category is 4 weeks delay. Model adjusted for age, gender,
smoking status, Carstairs deprivation quintile, Charlson index, place of
presentation, tumour grade, type of admission, and for symptoms and
signs of constipation, rectal bleeding, abdominal pain, anorexia, weight
loss and abdominal mass.
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Table 3. Relationship between patient and tumour factors and symptoms and signs with survival among CRC patients
Factor Total (n¼958) Deaths (n¼762) HR 99% CI
Provider delay median (IQR) weeks 17 (8,39) 17 (8, 39) 0.99 0.992, 0.999
Age median (IQR) years 71 (64, 78) 74 (67, 79) 1.04 1.03, 1.05
Gender
Male 540 (56.4) 439 (81.3) 1.18 0.98, 1.42
Female 418 (43.6) 323 (77.3) 1.00
Smoking status
Never smoked 358 (37.4) 270 (75.4) 1.00
Current smoker 149 (15.6) 117 (78.5) 1.14 0.86, 1.51
Ex-smoker 209 (21.8) 175 (83.7) 1.24 0.96, 1.59
Not known 242 (25.3) 200 (82.6) 1.33 1.04, 1.69
Carstairs deprivation quintile
1 (least deprived) 227 (24.1) 167 (73.6) 1.00
2 255 (27.0) 195 (76.5) 1.05 0.80, 1.37
3 231 (24.5) 204 (88.3) 1.43 1.09, 1.87
4 165 (17.5) 133 (80.6) 1.32 0.97, 1.77
5 (most deprived) 65 (6.9) 51 (78.5) 1.17 0.77, 1.76
Charlson index median (IQR) 1 (0,2) 2 (0,2) 1.16 1.12, 1.20
Tumour grade
Grade I 46 (4.9) 35 (76.1) 1.00
Grade II 571 (60.5) 434 (76.0) 1.09 0.69, 1.71
Grade III/IV 158 (16.7) 136 (86.1) 1.72 1.05, 2.80
Ungraded 169 (17.9) 145 (85.8) 1.75 1.08, 2.85
Place of original presentation
GP surgery 737 (76.9) 565 (76.7) 1.00
GP home visit 128 (13.4) 121 (94.5) 1.86 1.43, 2.41
GP out of hours visit 37 (3.9) 30 (81.1) 1.12 0.69, 1.83
Others 25 (2.6) 21 (84.0) 1.39 0.78, 2.46
Missing 31 (3.2) 25 (90.7) 1.29 0.76, 2.18
Type of admission
No emergency admission 699 (73.0) 539 (77.1) 1.00
Emergency admission 259 (27.0) 223 (86.1) 1.47 1.19, 1.80
Constipation
Yes 133 (13.9) 112 (84.2) 1.19 0.91, 1.55
No 825 (86.1) 650 (78.8) 1.00
Rectal bleeding
Yes 273 (28.5) 192 (70.3) 0.70 0.56, 0.87
No 685 (71.5) 570 (83.2) 1.00
Abdominal pain
Yes 273 (28.5) 224 (82.1) 1.14 0.93, 1.40
No 685 (71.5) 538 (78.5) 1.00
Anorexia
Yes 45 (4.7) 42 (93.3) 1.88 1.25, 2.83
No 913 (95.3) 720 (78.9) 1.00
Weight loss
Yes 94 (9.8) 82 (87.2) 1.33 0.98, 1.79
No 864 (90.2) 680 (78.7) 1.00
Abdominal mass
Yes 57 (6.0) 48 (84.21) 1.43 0.98, 2.11
No 901 (94.0) 714 (79.3) 1.00
Abbreviations: CI¼ confidence interval; CRC¼ colorectal cancer; GP¼general practitioner; HR¼ hazard ratio; IQR¼ inter-quartile range. Values are n (%) unless otherwise stated.
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since it is an intrinsic biological feature of the tumour less likely to
be affected by provider delay. Symptoms and signs are complex,
but, like emergency admission and place of presentation, are more
likely to be markers of disease progression than intermediate
variables. Hence, adjustment for grade, symptoms and signs,
emergency admissions and place of presentation was performed
since they may be markers for the more biologically aggressive
tumours believed to produce ‘waiting time paradox’ of poorest
outcome for those with shortest delays (Neal, 2009).
Context with other literature. In 2011, a Danish group addressed
several methodological weaknesses in earlier work by analysing
diagnostic delay in CRC as both a categorical and continuous
variable using RCSs. (Tørring et al, 2011). They analysed patients
with alarm symptoms separately from those with vague symptoms.
Patients with vague symptoms did not have better survival, causing
the authors to dispute the usual interpretation of the waiting time
paradox (i.e, the most biologically aggressive tumours are
diagnosed most quickly) since in this case, patients with vague
Table 4. Cox proportional hazards model to find the association between mortality and time to treatment as a continuous variable (4 week delay as reference)
Model 1 Model 2 Model 3 Model 4
HR (99% CI) HR (99% CI) HR (99% CI) HR (99% CI)
Provider delay (weeks)
4 1.00 1.00 1.00 1.00
20 0.81 (0.65 1.00) 0.92 (0.74 1.15) 0.94 (0.74 1.19) 0.99 (0.76 1.27)
40 1.01 (0.82 1.24) 1.12 (0.90 1.38) 1.10 (0.88 1.38) 1.17 (0.92 1.48)
60 1.05 (0.83 1.32) 1.20 (0.94 1.52) 1.17 (0.91 1.49) 1.21 (0.94 1.57)
Age 1.04 (1.03 1.05) 1.04 (1.03 1.05) 1.04 (1.03 1.04)
Gender
Male 1.27 (1.04 1.56) 1.26 (1.02 1.55) 1.28 (1.04 1.58)
Female 1.00 1.00 1.00
Smoking status
Non-smoker 1.00 1.00 1.00
Current smoker 1.25 (0.93 1.68) 1.27 (0.94 1.72) 1.25 (0.92 1.70)
Ex-smoker 1.17 (0.90 1.52) 1.15 (0.88 1.50) 1.18 (0.90 1.55)
Not known 1.20 (0.93 1.53) 1.18 (0.92 1.52) 1.20 (0.93 1.55)
Carstairs deprivation quintile
1 (least) 1.00 1.00 1.00
2 0.96 (0.72 1.26) 0.98 (0.74 1.30) 0.96 (0.72 1.27)
3 1.36 (1.03 1.79) 1.37 (1.04 1.82) 1.36 (1.03 1.81)
4 1.28 (0.95 1.74) 1.31 (0.96 1.78) 1.27 (0.93 1.73)
5 (most) 1.30 (0.85 1.98) 1.32 (0.86 2.01) 1.29 (0.84 1.97)
Place of presentation
GP surgery 1.00 1.00 1.00
GP home visit 1.19 (0.89 1.60) 1.20 (0.89 1.62) 1.22 (0.90 1.66)
GP out of hours visit 0.91 (0.55 1.50) 0.92 (0.55 1.53) 0.87 (0.52 1.46)
Others 1.18 (0.65 2.14) 1.18 (0.64 2.17) 1.25 (0.67 2.32)
Unknown 1.17 (0.68 1.99) 1.09 (0.61 1.94) 1.20 (0.67 2.16)
Charlson index 1.14 (1.09 1.18) 1.13 (1.08 1.18) 1.13 (1.08 1.18)
Grade
Grade I 1.00 1.00
Grade II 1.21 (0.76 1.93) 1.27 (0.79 2.02)
Grade III/IV 1.84 (1.11 3.02) 1.92 (1.16 3.18)
Ungradeable 1.58 (0.96 2.61) 1.64 (0.99 2.70)
Emergency admission 1.00 (0.78 1.29) 0.98 (0.76 1.28)
Symptoms and signs
Constipation 1.03 (0.77 1.37)
Rectal bleeding 0.84 (0.66 1.07)
Abdominal pain 1.17 (0.93 1.47)
Anorexia 1.69 (1.06 2.68)
Weight loss 1.29 (0.92 1.81)
Abdominal mass 1.56 (1.02 2.36)
Abbreviations: CI¼ confidence interval; GP¼general practitioner; HR¼ hazard ratio. Model 1: unadjusted model for time to treatment with four knots (4 week considered as reference)
Model 2: adjusted for place of presentation, patient age, patient gender, smoking status, Carstairs deprivation quintile and Charlson index Model 3: further adjusted for tumour grade and type
of hospital admission Model 4: further adjusted for symptoms and signs of constipation, rectal bleeding, abdominal pain, anorexia, weight loss and abdominal mass.
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symptoms and signs would have better overall survival. Instead,
they argued that the waiting time paradox is produced when
doctors expedite investigation and treatment of patients with
dramatic symptoms (i.e, those that have waited the longest to
present) and consequently a poorer prognosis. In patients
presenting with alarm symptoms, those with the shortest
diagnostic intervals had the poorest prognosis with 3-year
mortality dropping initially, but then climbing after 6 weeks, a
U-shaped curve. In contrast, for patients with vague symptoms, the
risk of 3-year mortality climbed from day 1 to week 12, although
the relationship was not statistically significant. The authors
concluded that the diagnostic interval does matter, especially in
patients without alarm symptoms. Our unadjusted mortality
analysis produced a similar curve, but once we adjusted for several
prognostic factors, not available to the Danish investigators, which
may confound the relationship between provider delay, stage-at-
presentation and mortality, the initial sharp downswing of the U
flattens out, as does the later upswing. This suggests that these
factors that are linked to tumour biology are more influential than
provider delays. The Danish investigators based their survival
analysis on survival from date of diagnosis, rather than date of first
presentation in primary care. For this reason we have also
performed a sensitivity analysis, where we have analysed survival
from date of treatment (or definitive diagnosis as recorded in the
Scottish Cancer Registry if no treatment). This has not appreciably
affected our results, interpretations or conclusions.
A further study by the same authors combined data from two
Danish datasets and one UK dataset (n¼ 1243) finding a similar
U-shaped association between mortality and diagnostic delay
(Tørring et al, 2012). Their combined results again support the
assertion that longer diagnostic intervals cause higher mortality in
patients with CRC, but again without accounting for many
important potential confounders (Tørring et al, 2012). Notably
this paper included a cohort from the UK, where survival began to
decline after B15 weeks, the same approximate relationship
observed in our unadjusted mortality analysis.
The current approach has incorporated the methodological
recommendations of Tørring et al (2011), but the nature of our
dataset has permitted a more complete and detailed adjustment
for particular symptoms and signs at diagnosis. Employing this
approach, we believe, our analysis is less at risk from
confounding.
Conclusions and implications. Prolonged provider delays before
assessment cause people who may have cancer, and their families,
anxiety and worry. Anxiety may be heightened by the commonly
held view that provider delays of even a few weeks can adversely
affect outcomes. In this sample of people diagnosed with CRC
between 1997 and 1998 longer provider delays did not lead to
poorer survival. While long delays are obviously undesirable, the
imposition of tight cancer waiting times targets could curtail
intensive preparation for major surgery, meaning resources are
not being used to support the best potential outcomes of
treatment (Tønnesen et al, 2009). There is also the risk that such
efforts divert research and resource from increasing public
awareness of cancer systems and reducing patient delays, which
are generally agreed to have greater impact on cancer outcomes
(Simon et al, 2010). Currently, the NHS prioritises waiting time
targets and they are measured by the government with adverse
publicity if they are not achieved. In turn, publicity around targets
may, inadvertently, increase anxiety experienced by patients and
relatives by reinforcing the unjustified belief that even modest
delays impact on survival. Whether the current emphasis on
awareness and early diagnosis in the UK will have any appreciable
impact on reducing premature mortality from CRC remains to be
proven, especially when compared with the biology of the
underlying cancer, delays might be less important to outcome
than is commonly believed.
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Figure 3. Spline curve of Cox proportional hazards regression of
provider delay (weeks) on hazard ratio for mortality. Model 1 (solid
line): unadjusted model with four knots (provider delay of 4 weeks used
as reference). Model 2 (dashed line): adjusted for place of presentation,
patient age, patient gender, smoking status, Carstairs deprivation
quintile and Charlson index. Model 3 (dotted line): further adjusted for
tumour grade and type of admission. Model 4 (long dash and dotted
line): further adjusted for symptoms and signs of constipation, rectal
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Figure 4. Spline curve of Cox proportional hazards model of provider
delay (weeks) on hazard ratio (shaded area are 99% CI) for mortality
after multi-adjustment for potential confounders. Reference category
is 4 weeks delay. Model adjusted for age, gender, smoking status,
Carstairs deprivation quintile, Charlson index, place of presentation,
tumour grade, type of admission, and for symptoms and signs of
constipation, rectal bleeding, abdominal pain, anorexia, weight loss
and abdominal mass.
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